Oppenheimer Holdings Research Analysts Lower Earnings Estimates for Sarepta Therapeutics Inc. (SRPT)
Sarepta Therapeutics Inc. (NASDAQ:SRPT) – Research analysts at Oppenheimer Holdings decreased their FY2017 earnings per share (EPS) estimates for Sarepta Therapeutics in a research report issued on Monday. Oppenheimer Holdings analyst M. Gilson now forecasts that the brokerage will post earnings per share of ($4.39) for the year, down from their previous forecast of ($4.00). Oppenheimer Holdings also issued estimates for Sarepta Therapeutics’ FY2018 earnings at ($2.86) EPS.
Sarepta Therapeutics (NASDAQ:SRPT) last issued its earnings results on Tuesday, July 19th. The company reported ($1.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.19) by $0.16. During the same quarter last year, the business posted ($0.87) EPS.
Several other research firms have also recently issued reports on SRPT. Royal Bank Of Canada reissued a “hold” rating and issued a $5.00 target price on shares of Sarepta Therapeutics in a research report on Friday, June 3rd. Vetr raised shares of Sarepta Therapeutics from a “strong sell” rating to a “buy” rating and set a $17.28 price target on the stock in a research report on Thursday, June 2nd. RBC Capital Markets raised shares of Sarepta Therapeutics from a “sector perform” rating to an “outperform” rating in a research report on Monday. William Blair reaffirmed a “market perform” rating on shares of Sarepta Therapeutics in a research report on Monday, June 27th. Finally, Needham & Company LLC lifted their price target on shares of Sarepta Therapeutics from $20.00 to $26.00 and gave the company a “buy” rating in a research report on Friday, July 22nd. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Sarepta Therapeutics currently has a consensus rating of “Buy” and an average price target of $51.01.
Shares of Sarepta Therapeutics (NASDAQ:SRPT) traded down 0.86% on Wednesday, hitting $55.25. 6,671,164 shares of the stock traded hands. The firm’s 50-day moving average is $28.17 and its 200 day moving average is $21.37. Sarepta Therapeutics has a 12-month low of $8.00 and a 12-month high of $58.87. The firm’s market cap is $2.65 billion.
Institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. increased its position in shares of Sarepta Therapeutics by 5.5% in the second quarter. Vanguard Group Inc. now owns 3,105,816 shares of the company’s stock valued at $59,227,000 after buying an additional 161,790 shares during the period. State Street Corp increased its position in shares of Sarepta Therapeutics by 25.3% in the second quarter. State Street Corp now owns 3,092,427 shares of the company’s stock valued at $58,976,000 after buying an additional 625,051 shares during the period. BlackRock Fund Advisors increased its position in shares of Sarepta Therapeutics by 2.2% in the first quarter. BlackRock Fund Advisors now owns 1,661,818 shares of the company’s stock valued at $32,439,000 after buying an additional 36,371 shares during the period. BlackRock Institutional Trust Company N.A. increased its position in shares of Sarepta Therapeutics by 2.5% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 1,068,913 shares of the company’s stock valued at $20,865,000 after buying an additional 25,799 shares during the period. Finally, Franklin Resources Inc. purchased a new position in shares of Sarepta Therapeutics during the first quarter valued at about $13,506,000. 72.09% of the stock is owned by institutional investors.
In other news, CEO Edward M. Md Kaye sold 24,557 shares of the business’s stock in a transaction on Wednesday, September 14th. The shares were sold at an average price of $30.00, for a total transaction of $736,710.00. Following the completion of the transaction, the chief executive officer now owns 76,983 shares of the company’s stock, valued at $2,309,490. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 10.90% of the company’s stock.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.
Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.